Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
PEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$148.00 - $310.00
Previous CloseN/A
Volume93.15K
Average Volume (3M)516.36K
Market Cap
$11.46B
Enterprise Value$10.31B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)274.9
Beta0.75
Next Earnings
Aug 05, 2025EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.83
Shares Outstanding38,725,940
10 Day Avg. Volume669,625
30 Day Avg. Volume516,362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda142.00
Forecast
1Y Price Target
$316.00Price Target Upside9.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Commercial Strategy ExecutionPEN's ability to effectively execute on its commercial strategy has increased analyst conviction.
Market Position And StrategyPEN continues to represent a highly attractive growth story within the MedTech universe with impressive momentum in large and underpenetrated commercial markets.
US VTE GrowthPEN posted 42% US VTE growth, marking a second consecutive quarter of over 40% growth for this business.
Bears Say
Manufacturing And InvestmentsManagement expects higher Thrombectomy product mix to be offset by higher manufacturing investments to support new product launches, which is expected to drive Q2/25 GM to be similar/lower than Q1/25.
Price Target ChallengesPEN's relative premium to profitable peers now sits at a fairly steep level, making it tough to lift the price target despite being a best-in-class innovator.
Product Performance SkepticismA doctor wasn't totally convinced that modulated aspiration would drive a significant enough change to patient outcomes.
---
Ownership Overview
3.52% Insiders
40.73% Mutual Funds
― Other Institutional Investors
33.93% Public Companies and
Individual Investors
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $310.00 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $11.46B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Aug 05, 2025 which is in 88 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Apr 23, 2025. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.667 by $0.163.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 0.83.
How many shares outstanding does Penumbra have?
Penumbra has 38,725,940 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.83 in its last earnings report, beating expectations of $0.667. Following the earnings report the stock price went up 6.988%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in PEN
---
Penumbra Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$316.00 (9.25% Upside)
$316.00 (9.25% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 82.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.96%
12-Months-Change
Fundamentals
Return on Equity
3.50%
Trailing 12-Months
Asset Growth
0.85%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. (PEN) is a global healthcare company specializing in innovative medical devices and technologies. The company primarily focuses on developing, manufacturing, and marketing products for treating a wide range of medical conditions, particularly in the fields of vascular and neurovascular health. Penumbra's core products include devices for thrombectomy, embolization, and access technologies used in procedures to address stroke, aneurysms, and other vascular conditions. The company is dedicated to advancing healthcare through research and development, producing solutions that cater to the needs of healthcare professionals and patients worldwide.
---
PEN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Penumbra, Inc. demonstrated strong financial performance with significant growth in the U.S. thrombectomy business and an improvement in gross margins. However, challenges in international markets, particularly in China, and flat gross margin expectations for Q2 present some concerns.Read More>---
PEN Stock 12 Month Forecast
Average Price Target
$316.00
▲(9.25% Upside)
Technical Analysis
---